Gal-9 primarily facilitates immunosuppression in the tumor microenvironment (TME) by interacting with multiple cell surface receptors on immune cells, such as TIM-3, Dectin-1 and CD44 3,6,7. The gene discussed is HAVCR2; the disease is neoplasm.